Herbert Ballentine Carter
#140,940
Most Influential Person Now
Herbert Ballentine Carter's AcademicInfluence.com Rankings
Herbert Ballentine Carterphilosophy Degrees
Philosophy
#7351
World Rank
#10554
Historical Rank
Logic
#4409
World Rank
#5697
Historical Rank
Download Badge
Philosophy
Why Is Herbert Ballentine Carter Influential?
(Suggest an Edit or Addition)Herbert Ballentine Carter's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. (1993) (1237)
- Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. (1992) (1120)
- Early detection of prostate cancer: AUA Guideline. (2013) (1061)
- Overdiagnosis and overtreatment of prostate cancer. (2014) (728)
- Complications after prostate biopsy: data from SEER-Medicare. (2011) (653)
- Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. (1990) (594)
- Active surveillance for prostate cancer: a systematic review of the literature. (2012) (585)
- Prostate specific antigen best practice statement: 2009 update. (2009) (556)
- Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. (1999) (506)
- Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. (2015) (466)
- Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. (2011) (432)
- Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. (1994) (399)
- Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. (2004) (335)
- Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies (2008) (330)
- Metabolic factors associated with benign prostatic hyperplasia. (2006) (313)
- Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. (2006) (301)
- Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. (1998) (293)
- Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. (2007) (272)
- Clinical evidence for and implications of the multistep development of prostate cancer. (1990) (261)
- Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. (1992) (254)
- Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. (2000) (237)
- Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. (2002) (231)
- Delayed versus immediate surgical intervention and prostate cancer outcome. (2006) (229)
- Plasma selenium level before diagnosis and the risk of prostate cancer development. (2001) (229)
- African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? (2013) (228)
- Prostate cancer early detection. Clinical practice guidelines in oncology. (2010) (226)
- Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. (2013) (189)
- Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. (2017) (185)
- Active surveillance for prostate cancer: current evidence and contemporary state of practice (2016) (183)
- Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. (1997) (181)
- Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. (1997) (177)
- Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. (2001) (177)
- Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. (1997) (176)
- 18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer (2015) (176)
- Gleason score 6 adenocarcinoma: should it be labeled as cancer? (2012) (169)
- Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. (2005) (167)
- Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. (2008) (163)
- Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. (2010) (156)
- Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. (2010) (155)
- NCCN clinical practice guidelines in oncology: prostate cancer early detection. (2010) (152)
- Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. (2000) (151)
- Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. (1995) (150)
- Evaluation of transrectal ultrasound in the early detection of prostate cancer. (1989) (145)
- Longitudinal evaluation of serum androgen levels in men with and without prostate cancer (1995) (140)
- Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men. (2014) (133)
- Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. (1999) (130)
- Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer. (2019) (128)
- American Urological Association (AUA) Guideline on prostate cancer detection: process and rationale (2013) (124)
- Effect of local anesthetics on patient recovery after transrectal biopsy. (2001) (122)
- Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. (2020) (122)
- Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. (2009) (120)
- The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of D (2014) (113)
- Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. (2012) (113)
- Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging. (2009) (111)
- Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. (2006) (109)
- Multiparametric magnetic resonance imaging findings in men with low‐risk prostate cancer followed using active surveillance (2013) (108)
- Prostate cancers in men with low PSA levels--must we find them? (2004) (107)
- Biopsy criteria for determining appropriateness for active surveillance in the modern era. (2014) (106)
- Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging. (2004) (99)
- What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? (2011) (98)
- Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. (2013) (97)
- Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. (1997) (97)
- Baseline prostate-specific antigen testing at a young age. (2012) (96)
- Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. (2001) (95)
- Serum testosterone is associated with aggressive prostate cancer in older men: results from the Baltimore Longitudinal Study of Aging (2010) (93)
- Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience (2007) (91)
- Nonsteroidal Anti-inflammatory Drugs and Risk of Prostate Cancer in the Baltimore Longitudinal Study of Aging (2005) (90)
- Risk stratification of men choosing surveillance for low risk prostate cancer. (2009) (90)
- Incidental renal tumors: casting doubt on the efficacy of early intervention. (2001) (87)
- PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. (2002) (86)
- Disparities in treatment and outcome for renal cell cancer among older black and white patients. (2007) (84)
- Importance of posterolateral needle biopsies in the detection of prostate cancer. (2001) (84)
- Natural history of changes in prostate specific antigen in early stage prostate cancer. (1994) (82)
- Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death (2017) (82)
- The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance. (2017) (81)
- Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? (2003) (79)
- Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies (2000) (79)
- Is repeat prostate biopsy associated with a greater risk of hospitalization? Data from SEER-Medicare. (2012) (78)
- Does high grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels? (1993) (75)
- Serum Testosterone and the Risk of Prostate Cancer: Potential Implications for Testosterone Therapy (2005) (74)
- Mixed-effects regression models for studying the natural history of prostate disease. (1994) (71)
- Estimating Unknown Transition Times Using a Piecewise Nonlinear Mixed-Effects Model in Men with Prostate Cancer (1995) (71)
- Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer. (1996) (69)
- Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging. (2002) (66)
- Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer (2018) (66)
- Prostate Health Index density improves detection of clinically significant prostate cancer (2017) (65)
- Reclassification rates are higher among African American men than Caucasians on active surveillance. (2015) (64)
- USE OF THE PROSTATE HEALTH INDEX FOR DETECTION OF PROSTATE CANCER: RESULTS FROM A LARGE ACADEMIC PRACTICE (2016) (63)
- Geometric evaluation of systematic transrectal ultrasound guided prostate biopsy. (2012) (63)
- Prostate Cancer Mortality following Active Surveillance versus Immediate Radical Prostatectomy (2012) (62)
- Pro–Prostate-Specific Antigen Measurements in Serum and Tissue Are Associated with Treatment Necessity among Men Enrolled in Expectant Management for Prostate Cancer (2009) (61)
- The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer. (1996) (61)
- Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. (2007) (60)
- Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. (1997) (60)
- Ureteral frozen section analysis during cystectomy: a reassessment. (1996) (59)
- Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis. (2013) (59)
- Prostate specific antigen testing among the elderly--when to stop? (2008) (59)
- Calcium intake and prostate cancer risk in a long-term aging study: the Baltimore Longitudinal Study of Aging. (2002) (58)
- Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy: Defining a Favorable Intermediate-Risk Group (2018) (57)
- ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program. (2011) (56)
- Prostate Cancer: The Magnitude of the Problem in the United States (1988) (55)
- Fine needle aspiration of the abnormal prostate: a cytohistological correlation. (1986) (55)
- Magnetic resonance-invisible versus magnetic resonance-visible prostate cancer in active surveillance: a preliminary report on disease outcomes. (2015) (53)
- Radical retropubic prostatectomy. How often do experienced surgeons have positive surgical margins when there is extraprostatic extension in the region of the neurovascular bundle? (2005) (53)
- Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor volume. (1995) (53)
- Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. (2008) (53)
- PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for Active Surveillance (2016) (52)
- Diagnostic challenges of clonal heterogeneity in prostate cancer. (2015) (51)
- PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. (2008) (51)
- Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. (2009) (50)
- PSA velocity for the diagnosis of early prostate cancer. A new concept. (1993) (48)
- Anatomic extent of pelvic lymph node dissection: impact on long-term cancer-specific outcomes in men with positive lymph nodes at time of radical prostatectomy. (2013) (47)
- Nonpalpable prostate cancer: detection with MR imaging. (1991) (47)
- Active surveillance versus surgery for low risk prostate cancer: a clinical decision analysis. (2012) (46)
- Clearance rate of serum‐free and total PSA following radical retropubic prostatectomy (1996) (45)
- Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. (2016) (44)
- Primary care providers' perspectives on discontinuing prostate cancer screening (2012) (44)
- Effect of treatment with 5‐α reductase inhibitors on progression in monitored men with favourable‐risk prostate cancer (2012) (43)
- The significance of prior benign needle biopsies in men subsequently diagnosed with prostate cancer. (1999) (43)
- Association of energy intake with prostate cancer in a long-term aging study: Baltimore Longitudinal Study of Aging (United States). (2003) (43)
- Modeling grade progression in an active surveillance study (2014) (42)
- A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer (2018) (42)
- Correlation of prostate cancer nuclear deoxyribonucleic acid, size, shape and Gleason grade with pathological stage at radical prostatectomy. (1992) (42)
- A PSA threshold of 4.0 ng/mL for early detection of prostate cancer: the only rational approach for men 50 years old and older. (2000) (40)
- Conditional probability of reclassification in an active surveillance program for prostate cancer. (2015) (38)
- Can stage A1 tumor extent be predicted by transurethral resection tumor volume, per cent or grade? A study of 64 stage A1 radical prostatectomies with comparison to prostates removed for stages A2 and B disease. (1991) (37)
- Tubularized neourethra following radical retropubic prostatectomy. (1993) (36)
- Longitudinal Assessment of Urinary PCA3 for Predicting Prostate Cancer Grade Reclassification in Favorable Risk Men during Active Surveillance (2017) (35)
- Variability in Medicare utilization and payment among urologists. (2015) (35)
- The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer. (1990) (35)
- Prostatic growth rate determined from MRI data: age-related longitudinal changes. (1999) (35)
- The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate. (2006) (35)
- Prostate-specific antigen testing for early diagnosis of prostate cancer: formulation of guidelines. (1999) (35)
- Characteristics and Experiences of Patients with Localized Prostate Cancer Who Left an Active Surveillance Program (2014) (34)
- Multicenter comparison of the diagnostic performance of free prostate-specific antigen. (1996) (34)
- Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts (2018) (34)
- Cell surface charge in predicting metastatic potential of aspirated cells from the Dunning rat prostatic adenocarcinoma model. (1988) (33)
- Prostate-specific antigen testing of older men. (1999) (32)
- Fluoroquinolone resistance in the rectal carriage of men in an active surveillance cohort: longitudinal analysis. (2015) (32)
- Management of low (favourable)‐risk prostate cancer (2011) (32)
- Radical prostatectomy outcome in men 65 years old or older with low risk prostate cancer. (2012) (31)
- Prostate cancer sampled on sextant needle biopsy: significance of cancer on multiple cores from different areas of the prostate. (1999) (31)
- The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer. (1996) (31)
- Performance of multiparametric magnetic resonance imaging in the evaluation and management of clinically low-risk prostate cancer. (2014) (31)
- Risk prediction tool for grade re‐classification in men with favourable‐risk prostate cancer on active surveillance (2017) (30)
- Efficacy of periprostatic local anesthetic for prostate biopsy analgesia: a meta-analysis. (2006) (30)
- Screening for prostate cancer by using random‐effects models (2003) (30)
- Today men with prostate cancer have larger prostates. (2000) (30)
- Prediction of metastatic potential in an animal model of prostate cancer: flow cytometric quantification of cell surface charge. (1989) (30)
- Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level. (2009) (29)
- Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols (2015) (29)
- Qualitative study on decision‐making by prostate cancer physicians during active surveillance (2017) (29)
- Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer. (2014) (29)
- Obesity does not adversely affect health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy. (2005) (28)
- Relationship between changes in prostate-specific antigen and prognosis of prostate cancer. (1993) (28)
- Robotic surgery in urological oncology: patient care or market share? (2015) (27)
- Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging. (2009) (27)
- Health-related quality-of-life outcomes after anatomic retropubic radical prostatectomy in the phosphodiesterase type 5 ERA: impact of neurovascular bundle preservation. (2005) (27)
- Primary care providers' response to the US Preventive Services Task Force draft recommendations on screening for prostate cancer. (2012) (27)
- Role of prostate-specific antigen velocity in prediction of final pathologic stage in men with localized prostate cancer. (1997) (27)
- Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline Summary. (2009) (27)
- Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics. (2012) (27)
- Comparison of DNA ploidy and nuclear size, shape and chromatin irregularity in tissue sections and smears of prostatic carcinoma. (1990) (26)
- Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent (2008) (26)
- Expectant treatment with curative intent in the prostate-specific antigen era: triggers for definitive therapy. (2006) (26)
- Improved biomarkers for prostate cancer: a definite need. (2004) (26)
- Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions. (2017) (26)
- Multiparametric Magnetic Resonance Imaging Characterization of Prostate Lesions in the Active Surveillance Population: Incremental Value of Magnetic Resonance Imaging for Prediction of Disease Reclassification (2013) (26)
- A Bayesian hierarchical model for prediction of latent health states from multiple data sources with application to active surveillance of prostate cancer (2015) (25)
- Significance of prostate adenocarcinoma perineural invasion on biopsy in patients who are otherwise candidates for active surveillance. (2011) (25)
- Variables influencing radiation exposure during extracorporeal shock wave lithotripsy. Review of 298 treatments. (1987) (25)
- The importance of pelvic lymph node dissection in men with clinically localized prostate cancer. (2006) (25)
- Prediction of the Pathologic Gleason Score to Inform a Personalized Management Program for Prostate Cancer. (2017) (24)
- Estimation of treatment benefits when PSA screening for prostate cancer is discontinued at different ages. (2005) (23)
- Assessing risk: does this patient have prostate cancer? (2006) (23)
- Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy. (2007) (23)
- Active surveillance for prostate cancer: an underutilized opportunity for reducing harm. (2012) (22)
- Prostate cancer diagnosis. (1994) (22)
- Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, Carter HB.J Clin Oncol. 2015 Oct 20;33(30):3379-85. [Epub 2015 Aug 31]. doi: 10.1200/JCO.2015.62.5764. (2017) (21)
- Managing high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical glands on prostate biopsy (2018) (21)
- Is preoperative donation of autologous blood rational for radical retropubic prostatectomy? (2000) (21)
- Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance (2020) (21)
- Expectant management of localized prostate cancer. (2003) (20)
- Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program (2010) (20)
- Prostate-Specific Antigen (PSA) Screening for Prostate Cancer: Revisiting the Evidence. (2018) (20)
- The Mind (2015) (19)
- Update on watchful waiting for prostate cancer (2004) (19)
- Rationale for earlier and less frequent prostate cancer screening. (2001) (19)
- Overdetection of Recurrence after Radical Prostatectomy: Estimates Based on Patient and Tumor Characteristics (2014) (18)
- Outcomes of men with an elevated prostate‐specific antigen (PSA) level as their sole preoperative intermediate‐ or high‐risk feature (2014) (18)
- Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial. (2020) (17)
- Serum prostate‐specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density (2014) (17)
- Practice patterns and individual variability of surgeons performing radical prostatectomy at a high volume academic center. (2015) (17)
- Distribution of PSA velocity by total PSA levels: data from the Baltimore Longitudinal Study of Aging. (2011) (17)
- In-office Transperineal Prostate Biopsy Using Biplanar Ultrasound Guidance: a Step-by-Step Guide. (2019) (16)
- Prostate Volumetric Assessment by Magnetic Resonance Imaging and Transrectal Ultrasound: Impact of Variation in Calculated Prostate-Specific Antigen Density on Patient Eligibility for Active Surveillance Program (2013) (16)
- PTEN Status Assessment in the Johns Hopkins Active Surveillance Cohort (2018) (16)
- Relationship between changes in prostate-specific antigen and the percent of prostatic epithelium in men with benign prostatic hyperplasia. (1995) (16)
- Early Detection, Diagnosis, and Staging of Prostate Cancer (2012) (15)
- Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance (2019) (15)
- Effect of intra‐observer variation in prostate volume measurement on prostate‐specific antigen density calculations among prostate cancer active surveillance participants (2011) (15)
- Improving Prostate Cancer Screening and Diagnosis: Health Policy and Biomarkers Beyond PSA. (2016) (14)
- DNA content in the diagnostic biopsy for benign‐adjacent and cancer‐tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management programme (2010) (14)
- The role of prostate-specific antigen velocity in prostate cancer early detection (2000) (13)
- A Novel Quantitative Multiplex Tissue Immunoblotting for Biomarkers Predicts a Prostate Cancer Aggressive Phenotype (2015) (13)
- Prediction of significant cancer in men with stage Tic adenocarcinoma of the prostate (2005) (13)
- Prostate specific antigen best practice statement: 2009 update. (2013) (13)
- Overview of hormonal therapy for prostate cancer. (1990) (13)
- Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy. (2007) (12)
- Informational needs during active surveillance for prostate cancer: A qualitative study. (2017) (12)
- Does prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of aging. (2008) (12)
- Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy. (2012) (12)
- Do Environmental Factors Modify the Genetic Risk of Prostate Cancer? (2014) (11)
- Predictors of Adverse Pathology in Men Undergoing Radical Prostatectomy Following Initial Active Surveillance. (2014) (11)
- Update on PSA testing. (2007) (11)
- Letters to the Editor/Errata Re: Early Detection of Prostate Cancer: AUA guideline (2013) (11)
- PSA variability versus velocity. (1997) (10)
- Drug and device development for localized prostate cancer: report of a Food and Drug Administration/American Urological Association public workshop. (2014) (10)
- Expectant Management of Prostate Cancer with Curative Intent (2001) (9)
- Use of spinal anesthesia does not reduce intraoperative blood loss. (2007) (9)
- Prediagnostic plasma vitamin C levels and the subsequent risk of prostate cancer. (2005) (9)
- Heterogeneity in active surveillance protocols worldwide. (2014) (9)
- 439: Higher Serum Free Testosterone is Associated with an Increased Risk of Prostate Cancer: Results from the Baltimore Longitudinal Study on Aging (2004) (9)
- Influence of Testosterone on the GH—IGF-I Axis in Healthy Elderly Men (1999) (9)
- PROSTATIC GROWTH RATE DETERMINED FROM MRI DATA: AGE RELATED LONGITUDINAL CHANGES (1999) (9)
- The relationship between prostate volume and prostate‐specific antigen variability: data from the Baltimore Longitudinal Study of Aging and the Johns Hopkins Active Surveillance Program (2012) (9)
- 951: PSA Velocity and Risk of Prostate Cancer Death in the Baltimore Longitudinal Study of Aging (2005) (9)
- Newer diagnostic techniques for bladder cancer. (1987) (8)
- Rebuttal from Authors re: Axel Heidenreich. Identification of High-Risk Prostate Cancer: Role of Prostate-Specific Antigen, PSA Doubling Time and PSA Velocity. Eur Urol 2008;54:976–7 (2008) (8)
- Repeat prostate biopsies predict location of index cancer in an active surveillance cohort (2011) (8)
- Interpretation of the prostate‐specific antigen history in assessing life‐threatening prostate cancer (2010) (8)
- ESTIMATING AND COMPARING CANCER PROGRESSION RISKS UNDER VARYING SURVEILLANCE PROTOCOLS. (2018) (8)
- Can a baseline prostate specific antigen level identify men who will have lower urinary tract symptoms later in life? (2005) (8)
- 1743: Risk Count Assessment: A New Concept for Detection of Life Threatening Prostate Cancer During a Window of Curability (2007) (8)
- Association of quantitative magnetic resonance imaging parameters with histological findings from MRI/ultrasound fusion prostate biopsy. (2014) (8)
- Targeted antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy during active surveillance: Effect on hospitalization. (2018) (8)
- Optimizing Active Surveillance. (2016) (8)
- Association between Liver Fibrosis and Serum PSA among U.S. Men: National Health and Nutrition Examination Survey (NHANES), 2001–2010 (2019) (8)
- Germline mutations in PPFIBP2 are associated with lethal prostate cancer (2018) (7)
- 1344: Metabolic Factors Associated with Benign Prostatic Hyperplasia: The Baltimore Longitudinal Study of Aging (2006) (7)
- Informed consent for prostate-specific antigen screening. (2003) (7)
- Magnetic Resonance-Guided Prostate Biopsy. (2015) (7)
- Evaluation of changes in PSA in the management of men with prostate cancer. (1994) (7)
- 1623: Biological Variation of PCA3 Score in Men Previously Diagnosed with Prostate Cancer (2007) (6)
- Value of transition zone biopsy in active surveillance of prostate cancer. (2014) (6)
- Prostate-specific antigen and all-cause mortality: results from the Baltimore Longitudinal Study On Aging. (2004) (6)
- Active Surveillance of Localized Prostate Cancer: Acknowledging Uncertainty. (2016) (6)
- The biology of prostate cancer: new and future directions in predicting tumor behavior. (1992) (6)
- RATIONAL PSA SCREENING STRATEGIES FOR PROSTATE CANCER: COMPUTER SIMULATIONS OF AGE RANGES, PSA CUTOFFS, AND TESTING INTERVALS (1999) (6)
- A clinicopathologic study of preoperative and postoperative findings with minute Gleason 3+3=6 cancer at radical prostatectomy. (2008) (6)
- Multiparametric magnetic resonance imaging (MRI) and active surveillance for prostate cancer: future directions (2014) (6)
- Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts (2020) (6)
- Editorial: Prostate Cancer Diagnosis (1994) (6)
- Active surveillance of prostate cancer: Current state of practice and utility of multiparametric magnetic resonance imaging. (2017) (6)
- Prostate-specific antigen in men born with bladder exstrophy. (1997) (6)
- Experimental and theoretical basis for hormonal treatment of prostatic cancer. (1988) (6)
- Isolated vasculitis of the seminal vesicle. (1998) (5)
- Words of wisdom. Re: Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. (2009) (5)
- PREDIAGNOSTIC SERUM SELENIUM LEVELS AND THE RISK OF PROSTATE CANCER DEVELOPMENT (1999) (5)
- Response to editorial comment (2010) (5)
- 654: Pathological Outcomes are Similar for Men in an Expectant Management Program Undergoing Delayed Surgical Intervention Compared to Those Undergoing Immediate Intervention (2006) (5)
- Clinical Evaluation of an Individualized Risk Prediction Tool for Men on Active Surveillance for Prostate Cancer. (2018) (4)
- Radical Prostatectomy Findings in Men on Active Surveillance: Variable Findings Dependent on Reason for Surgery and Entry Criteria. (2015) (4)
- 2096 HOW SAFE IS PROSTATE BIOPSY? RATE OF COMPLICATIONS REQUIRING HOSPITALIZATION FOLLOWING PROSTATE BIOPSY IN SEER-MEDICARE (2010) (4)
- Bayesian Joint Hierarchical Model for Prediction of Latent Health States with Application to Active Surveillance of Prostate Cancer (2015) (4)
- IMPORTANCE OF POSTEROLATERAL NEEDLE BIOPSIES OF THE PROSTATE IN THE DETECTION OF PROSTATE CANCER (1999) (4)
- Point: Impact of prostate-specific antigen velocity on management decisions and recommendations. (2013) (3)
- Re: Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening. (2015) (3)
- Investigation of human anti-mouse antibodies as potential cause of postprostatectomy PSA elevation. (2009) (3)
- The association between clinically determined periodontal disease and prostate-specific antigen concentration in men without prostate cancer: the 2009–2010 National Health and Nutrition Examination Survey (2019) (3)
- MP51-05 RECLASSIFICATION RATES ARE HIGHER AMONG AFRICAN AMERICAN MEN THAN WHITE MEN ON ACTIVE SURVEILLANCE (2014) (3)
- Limitations and use of PSA derivatives in the screening and risk stratification of prostate cancer. (2009) (3)
- Stromal Tumor of Uncertain Malignant Potential (STUMP) With PSA >500 ng/ml: A Case Report (2015) (3)
- SERUM TESTOSTERONE IS ASSOCIATED WITH AGGRESSIVE PROSTATE CANCER: RESULTS FROM THE BALTIMORE LONGITUDINAL STUDY OF AGING (2008) (3)
- MP48-12 ACTIVE SURVEILLANCE OF VERY LOW AND LOW RISK PROSTATE CANCER: LONG-TERM OUTCOMES FROM A LARGE PROSPECTIVE COHORT (2019) (3)
- 194: Obesity does not Negatively Impact on Health Related Quality of Life Outcomes after Anatomic Retropubic Radical Prostatectomy (2005) (2)
- The Role of Prostate-Specific Antigen Velocity in the Diagnosis and Management of Prostate Cancer (2008) (2)
- Active surveillance for favorable risk prostate cancer. (2015) (2)
- PD50-04 UTILITY OF MULTIPARAMETRIC MRI IN THE RISK STRATIFICATION OF MEN WITH GRADE GROUP 1 PROSTATE CANCER ON ACTIVE SURVEILLANCE (2019) (2)
- Re: long-term followup after laparoscopic radical nephrectomy. (2002) (2)
- Reducing prostate cancer deaths: unsupported speculation about the androgen deprivation hypothesis. (2014) (2)
- Prostate cancer in patients with the bladder exstrophy-epispadias complex: insights and outcomes. (2008) (2)
- Abstract 4352: Prediction of prostate cancer progression with biomarkers and tissue morphometry changes (2015) (2)
- 84 – Prostate Cancer (2014) (2)
- Prostate health index and multiparametric MRI to predict prostate cancer grade reclassification in active surveillance (2018) (2)
- PSA scores: should we use a lower threshold? (2004) (2)
- 1677 ELEVATED BODY MASS INDEX IS ASSOCIATED WITH FUTURE ERECTILE DYSFUNCTION (2011) (2)
- Risk Stratification in Active Surveillance: A Dynamic, Ever-Evolving Practice. (2018) (1)
- 1632 EFFECT OF INTRA-OBSERVER VARIATION IN PROSTATE VOLUME CALCULATIONS IN PROSTATE CANCER ACTIVE SURVEILLANCE GROUP (2011) (1)
- SIGNIFICANCE OF PRIOR NEGATIVE NEEDLE BIOPSIES IN MEN SUBSEQUENTLY DIAGNOSED WITH PROSTATE CANCER (1999) (1)
- Why do cells metastasize? (1990) (1)
- 289 ANATOMICAL EXTENT OF LYMPH NODE DISSECTION: IMPACT ON MEN WITH POSITIVE LYMPH NODES AT TIME OF RADICAL PROSTATECTOMY (2011) (1)
- Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment (2021) (1)
- Prostate cancer screening (2002) (1)
- 188 Watchful waiting in patients with prostate cancer – US (2009) (1)
- Association Between Liver Fibrosis and Serum Prostate Specific Antigen (PSA) 1 Among US Men: National Health and Nutrition Examination Survey (NHANES) 2 2001–2010 (2019) (1)
- Definitive therapy for men with newly-diagnosed oligometastatic prostate cancer: Initial surgical outcomes from a phase II study (2018) (1)
- Patient Selection for Active Surveillance (2012) (1)
- MP46-05 DEVELOPMENT OF A CLINICAL IMPLEMENTATION PLAN (CAREPATH) FOR A NOVEL URINE EXOSOME GENE EXPRESSION ASSAY AS PART OF A TWO-COHORT, ADAPTIVE DECISION IMPACT UTILITY TRIAL (2018) (1)
- Evaluation of apparent diffusion coefficient as a predictor of grade reclassification in men on active surveillance for prostate cancer. (2020) (1)
- Editorial Comments: Cryosurgical Treatment of Localized Prostate Cancer (Stages T1 to T4) (1996) (1)
- Prostate-specific antigen velocity and repeated measures of prostate-specific antigen : Prostate-specific antigen: the best prostatic tumor marker (1997) (1)
- Patients with Intermediate Risk Prostate Cancer May be Good Candidates for Active Surveillance: Con. (2017) (1)
- Aligning evidence and practice: future research needs to increase utilization of active surveillance for favorable risk prostate cancer (2015) (1)
- GERMLINE MUTATIONS IN DNA REPAIR GENES ARE SIGNIFICANTLY ENRICHED IN LETHAL PROSTATE CANCER AND ARE ASSOCIATED WITH DISEASE SURVIVAL: MP57‐01 (2017) (1)
- PD6-04 A PROSPECTIVE, LONGITUDINAL ACTIVE SURVEILLANCE PROGRAM FOR FAVORABLE-RISK PROSTATE CANCER: LONG TERM OUTCOMES (2015) (1)
- MP40-10 EXTENDED VALIDATION RESULTS FROM A PROSPECTIVE ADAPTIVE UTILITY TRIAL CONFIRM PERFORMANCE OF A NOVEL URINE EXOSOME GENE EXPRESSION ASSAY TO PREDICT HIGH-GRADE PROSTATE CANCER AT INITIAL BIOPSY (2018) (1)
- Editorial Comment: Clinical and Pathological Features of Hereditary Prostate Cancer (1996) (1)
- 1434: Predicting the Need for Treatment among Men with Low Grade, Low Stage Prostate Cancer Enrolled in a Program of Expectant Management with Curative Intent (2007) (1)
- Helping to address the over treatment of prostate cancer: tools to differentiate lethal and non-lethal phenotype in prostate cancer. (2012) (1)
- American Urological Association ( AUA ) Guideline EARLY DETECTION OF PROSTATE CANCER : AUA GUIDELINE (2018) (1)
- Current status of PSA in the management of prostate cancer. (1994) (1)
- Reply to P.F. Pinksy (2011) (1)
- 1730 WHAT IS THE TRUE NUMBER-NEEDED-TO-SCREEN AND TREAT TO SAVE A LIFE WITH PSA SCREENING? (2010) (1)
- MP12-20 PROSTATE HEALTH INDEX AND MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING TO PREDICT PROSTATE CANCER GRADE RECLASSIFICATION IN ACTIVE SURVEILLANCE (2018) (1)
- MP1-15 QUANTITATIVE HISTOMORPHOMETRIC ANALYSIS OF PROSTATE BIOPSY IMAGES PREDICT FAVORABLE OUTCOME IN ACTIVE SURVEILLANCE PATIENTS (2015) (1)
- Prostate-specific antigen-based screening for prostate cancer: the irony of it all. (2013) (1)
- PSA KINETICS ALONE ARE AN UNRELIABLE TRIGGER FOR INTERVENTION IN A PROSTATE CANCER SURVEILLANCE PROGRAM (2009) (1)
- RATIO OF SERUM PRO-PSA TO FRACTION SERUM FREE PSA PREDICTS THE NEED FOR TREATMENT AMONG MEN WITH LOW GRADE, LOW STAGE PROSTATE CANCER ENROLLED IN AN EXPECTANT MANAGEMENT PROGRAM (2009) (1)
- Continued undertreatment of older men with localized prostate cancer. (2004) (1)
- 1726 BODY MASS INDEX IN YOUNG MEN IS ASSOCIATED WITH PROSTATE ENLARGEMENT LATER IN LIFE (2011) (1)
- 1626: Surveillance of Men with Low Grade and Stage Prostate Cancer Enrolled in an Expectant Management Program: Changes in Clinical, Pathological and Nuclear Morphometry Patterns Observed Over Time (2007) (1)
- MP07-15 UTILITY OF PTEN/ERG STATUS IN A CONTEMPORARY COHORT OF MEN WITH FAVORABLE-RISK PROSTATE CANCERS (2016) (1)
- PD08-01 PREDICTION OF THE CANCER STATE TO INFORM A PERSONALIZED MANAGEMENT PROGRAM FOR PROSTATE CANCER (2016) (1)
- Baseline PSA testing for men in their 40s: testing in average-risk men aged 40 to 50 years should not be routinely performed. (2014) (0)
- Reply from Authors re: Seth A. Strope, Gerald L. Andriole. Prostate-Specific Antigen–Based Risk Assessment in Younger Men. Eur Urol 2012;61:8–9 (2012) (0)
- Heterogeneous random-effects models for screening of prostate cancer (2003) (0)
- BONE MINERAL CONTENT AND PROSTATE CANCER: THE SEED AND SOIL HYPOTHESIS (2009) (0)
- 2051 SERUM PROSTATE HEALTH INDEX AND BIOPSY TISSUE DNA CONTENT AT THE TIME OF DIAGNOSIS PREDICTS THE NEED FOR TREATMENT IN MEN ENROLLED IN AN ACTIVE SURVEILLANCE PROGRAM (2010) (0)
- Abstract 2731: Serum prostate health index and biopsy tissue DNA content at the time of diagnosis predicts the need for treatment in men enrolled in an active surveillance program (2010) (0)
- MP42-04 ACTIVE SURVEILLANCE: WHEN CAN PATIENTS STOP WORRYING? (2015) (0)
- Use of 5- (cid:1) -Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/ American Urological Association 2008 Clinical Practice Guideline (2009) (0)
- Chapter 4 – Expectant Management (2010) (0)
- encouraging, suggesting that future screening protocols may be improved through the integration of genetic information. Is this ready for prime time? Not yet—prospective validation studies are necessary to determine whether genotype adjusted PSA thresholds will improve clinical outcomes. (2011) (0)
- Genomic Alterations in Prostatic Cancer (1991) (0)
- MP12-03 FAVORABLE INTERMEDIATE-RISK PROSTATE CANCER LEADS TO WORSE SURVIVAL COMPARED TO LOW-RISK PATIENTS DUE TO ADVERSE PATHOLOGY (2018) (0)
- Evaluating a polygenic hazard score to predict risk of developing metastatic or fatal prostate cancer in the multi-ancestry Million Veteran Program cohort (2021) (0)
- Reply by Authors. (2019) (0)
- THE RELATIONSHIP BETWEEN PROSTATE VOLUME CHANGES AND PSA VELOCITY IN A LONGITUDINAL AGING STUDY (2008) (0)
- Editorial comment. (2012) (0)
- 644: Estimation of Treatment Benefits When Prostate Cancer Screening is Discontinued at Different Ages (2004) (0)
- 931 DO SURVEILLANCE BIOPSIES PREDICT THE LOCATION OF THE INDEX CANCER IN PATIENTS IN AN ACTIVE SURVEILLANCE PROGRAM (2010) (0)
- Roehrborn CG, Albertsen P, Stokes ME, Black L, Benedict A. First-year costs of treating prostate cancer: estimates from SEER-Medicare data. Prostate Cancer Prostatic Dis 2009. In press. (2009) (0)
- Editorial Comment. (2022) (0)
- 2025 CAN A SINGLE PSA MEASUREMENT AT AGE 60–70 YEARS IDENTIFY MEN WHO NEED NO FURTHER PSA TESTING? (2011) (0)
- loss chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active (2016) (0)
- 1278: Obesity is a Predictor of Increased Prostate Volume (2005) (0)
- PTEN status assessment in the Johns Hopkins active surveillance cohort (2018) (0)
- PSA Testing in Prostate Cancer: Early Treatment vs Observation (2014) (0)
- 401 UTILITY OF PSA VELOCITY FOR PREDICTION OF GLEASON SCORE UPGRADING BETWEEN BIOPSY AND RADICAL PROSTATECTOMY (2010) (0)
- PSA Thresholds for Prostate Cancer Detection-Reply (1997) (0)
- Prostate cancer screening in 2014 : The debate rages on Highlights of presentations by Drs . (0)
- 933 PSA FREE OUTCOMES AFTER RADICAL PROSTATECTOMY AMONG MEN INITIALLY MANAGED WITH ACTIVE SURVEILLANCE FOR PROSTATE CANCER: JOHNS HOPKINS EXPERIENCE (2010) (0)
- Legends in Urology. (2019) (0)
- PSA THRESHOLDS FOR PROSTATE CANCER DETECTION. AUTHORS' REPLY (1997) (0)
- Healthy lifestyle and Agent Orange exposure modulate inherited prostate cancer risk: An analysis of the Million Veteran Program. (2022) (0)
- Overview Prostate cancer is the most commonly diagnosed The NCCN Prostate Cancer Early Detection Clinical Practice Guidelines in OncologyTM (2010) (0)
- 928 SHOULD TRANSITION ZONE BIOPSIES BE A STANDARD FOR PROSTATE CANCER SURVEILLANCE (2010) (0)
- Reply to M.C. Scholz et al. (2016) (0)
- IS BODY MASS INDEX ASSOCIATED WITH PROSTATE CANCER AGGRESSIVENESS? DATA FROM THE BALTIMORE LONGITUDINAL STUDY OF AGING (2009) (0)
- Reply: To PMID 25440986. (2015) (0)
- MP17-01 HETEROGENEITY IN DETECTION RATES OF HIGHER GRADE PROSTATE CANCER BY MULTIPARAMETRIC MRI IN AN ACTIVE SURVEILLANCE COHORT (2018) (0)
- MP90-10 SERUM TESTOSTERONE LEVELS PRIOR TO PROSTATE CANCER DIAGNOSIS (2016) (0)
- Running Foot: 18 F-DCFBC Imaging of Primary Prostate Cancer (2015) (0)
- Bone mineral content and prostate cancer risk: data from the Baltimore Longitudinal Study of Aging (2010) (0)
- 1062 PATHOLOGIC STAGE AND IMPLICATIONS FOR CURE IN ACTIVE SURVEILLANCE PATIENTS WHO UNDERGO RADICAL PROSTATECTOMY (2010) (0)
- MP24-16 VARIABILITY IN MEDICARE UTILIZATION AND PAYMENT AMONG UROLOGISTS (2015) (0)
- Technique determines efficacy of local anesthetic for outpatient prostate biopsy (2001) (0)
- PD20-04 GERMLINE MUTATIONS IN DNA REPAIR GENES ARE INDEPENDENT PREDICTORS OF GRADE RECLASSIFICATION IN ACTIVE SURVEILLANCE FOR PROSTATE CANCER PATIENTS (2018) (0)
- PD31-04 DO ENVIRONMENTAL FACTORS MODIFY THE GENETIC RISK OF PROSTATE CANCER? (2014) (0)
- Editorial Comment. (2019) (0)
- PROSTATE SPECIFIC ANTIGEN VARIATION IN PATIENTS WITHOUT CLINICALLY EVIDENT PROSTATE CANCER (1999) (0)
- PROSTATE‐SPECIFIC ANTIGEN VELOCITY (PSAV) RISK COUNT IMPROVES THE SPECIFICITY OF SCREENING FOR CLINICALLY SIGNIFICANT PROSTATE CANCER (2012) (0)
- PD08-06 RISK PREDICTION TOOL FOR GRADE RECLASSIFICATION IN FAVORABLE-RISK MEN ON ACTIVE SURVEILLANCE (2016) (0)
- Nonpalpable prostate cancer detected in the prostate-specific antigen era (2005) (0)
- 2323 [-2]PROPSA PREDICTS BIOPSY RECLASSIFICATION IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER (2011) (0)
- Should prostate-specific antigen velocity be abandoned? (2011) (0)
- The 9th American Urological Association and the Japanese Urological Association International Affiliate Society Meeting (2014) (0)
- Preliminary evaluation of 18F-DCFBC PSMA PET for detection of primary prostate cancer (2013) (0)
- Stratifying Risk for Men With Low-Volume Intermediate-Risk Prostate Cancer-Reply. (2018) (0)
- PD34-02 PRACTICE PATTERNS OF UROLOGISTS PERFORMING RADICAL PROSTATECTOMIES AT A HIGH-VOLUME CENTER: INDIVIDUAL SURGEON VARIABILITY (2014) (0)
- EDITORIAL: TREATMENT OF PROSTATE CANCER-A CONTROVERSIAL ISSUE (1997) (0)
- Consultation corner. Prostate screening: refining what PSA levels mean. (2007) (0)
- Abstract 129: Biobanking and feasibility considerations for prostate cancer gastrointestinal microbiome studies (2018) (0)
- Editorial comment. (2009) (0)
- MP9-02 OLDER AGE PREDICTS GLEASON SCORE UPGRADING DURING LONG-TERM MONITORING ON ACTIVE SURVEILLANCE (2015) (0)
- Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features: Editorial comment (2002) (0)
- Editorial comment. (2009) (0)
- 2133 THE RELATIONSHIP BETWEEN PROSTATE VOLUME AND PSA VARIABILITY: DATA FROM THE BALTIMORE LONGITUDINAL STUDY OF AGING AND THE JOHNS HOPKINS ACTIVE SURVEILLANCE PROGRAM (2010) (0)
- 1416: Does a Confirmation Biopsy after Prostate Cancer Diagnosis Reduce the Number of Men who Progress in an Expectant Management Program? (2007) (0)
- MP48-09 GRADE RECLASSIFICATION IN ACTIVE SURVEILLANCE FOR AFRICAN AMERICAN MEN WITH VERY LOW RISK PROSTATE CANCER (2019) (0)
- PD34-09 COMPARISON OF PATHOLOGIC OUTCOMES IN MEN WITH FAVORABLE-RISK PROSTATE CANCER UNDERGOING DELAYED SURGERY AFTER ACTIVE SURVEILLANCE VERSUS IMMEDIATE SURGERY (2015) (0)
- MP22-14 DEFINITIVE THERAPY FOR MEN WITH NEWLY-DIAGNOSED OLIGOMETASTATIC PROSTATE CANCER: INITIAL SURGICAL OUTCOMES FROM A PHASE II STUDY (2018) (0)
- Treatment of prostate cancer--a controversial issue. (1997) (0)
- 730: Health Related Quality of Life Outcomes after Anatomic Retropubic Radical Prostatectomy: Impact of Neurovascular Bundle Preservation (2005) (0)
- PD13-06 EFFECT OF PHARMACOLOGIC PROPHYLAXIS ON VENOUS THROMBOEMBOLISM AFTER RADICAL PROSTATECTOMY: THE PREVENTER RANDOMIZED CLINICAL TRIAL (2020) (0)
- MP15-08 IS PSA DENSITY OR PSA (OR NEITHER) USEFUL TO PREDICT BIOPSY RECLASSIFICATION IN ACTIVE SURVEILLANCE PATIENTS? (2016) (0)
- 1638 EFFECTS OF 5-ALPHA REDUCTASE INHIBITOR USE IN MONITORED MEN WITH VERY-LOW RISK PROSTATE CANCER (2011) (0)
- Use of 2.6 NG/ML prostate specific antigen prompt for biopsy in men older than 60 years: Editorial comment (2005) (0)
- Applied nutritional investigation Prediagnostic plasma vitamin C levels and the subsequent risk of prostate cancer (2005) (0)
- Re: an empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. (2011) (0)
- Editorial comment. (2010) (0)
- The current management of carcinoma of the prostate. (1999) (0)
- Title: 18 F-DCFBC PET/CT for PSMA-based Detection and Characterization of Primary Prostate Cancer F-DCFBC Imaging of Primary Prostate Cancer (2015) (0)
- MP12-09 APPARENT DIFFUSION COEFFICIENT PREDICTS RISK OF GRADE RECLASSIFICATION IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER (2018) (0)
- NIH MP 43-18 FOR MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER , OLDER AGE AT DIAGNOSIS AND AT RADICAL PROSTATECTOMY PORTENDS POOR OUTCOMES (2017) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Herbert Ballentine Carter?
Herbert Ballentine Carter is affiliated with the following schools:
